Pharmacokinetic parameters for ALPZ at baseline and after administration of a valerian extract for 14 days
Values in parentheses indicate 95% confidence intervals. There were no significant differences in any other parameters between baseline and valerian phases.
Parameter | Baseline | After Valerian | Geometric Mean Ratio of Baseline to Valerian Phase and 95% CI |
|---|---|---|---|
| % | |||
| Cmax (ng/ml) | 25 ± 7 | 31 ± 8a | NA |
| Tmax (h) | 3.0 ± 3.2 | 3.0 ± 2.1 | NA |
| AUC0-inf(h · ng · ml-1) | 471 ± 183 | 539 ± 240 | 88.9 |
| (86.2-93.7) | |||
| AUC0-last timepoint(h · ng · ml-1) | 397 ± 138 | 489 ± 198 | 82.9 |
| (80.3-87.2) | |||
| Apparent oral clearance (l/h) | 4.9 ± 2.0 | 4.4 ± 1.8 | NA |
| Half-life of elimination (h) | 13.5 ± 4.3 | 12.2 ± 5.6 | 115.6 |
|
|
|
| (107.3-130.4) |
NA, not applicable.
↵ a The Cmax of ALPZ was increased after administration of valerian (P < 0.05).